Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 15/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | CALML3 | P27482 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12674052 | 1.00 | GRM2 (0.37) | GRM2MAOACALML3HTR6 | |
| Hydrochloric Acid SCHEMBL7081708 | 0.99 | GRM2 (0.37) | GRM2MAOACALML3 | |
| Hydrochloric Acid SCHEMBL7081703 | 0.99 | GRM2 (0.37) | GRM2MAOACALML3 | |
| SCHEMBL7082771 | 0.90 | MAOA (0.44) | MAOACALML3 | |
| Hydrochloric Acid SCHEMBL7084342 | 0.90 | MAOA (0.44) | MAOACALML3 | |
| Hydrochloric Acid SCHEMBL7084340 | 0.90 | MAOA (0.44) | MAOACALML3 | |
| SCHEMBL7081834 | 0.87 | GRM2 (0.43) | GRM2 | |
| SCHEMBL7078515 | 0.84 | GRM2 (0.38) | GRM2MAOA | |
| SCHEMBL7081043 | 0.83 | GRM2 (0.38) | GRM2MAOA | |
| Hydrochloric Acid SCHEMBL7078521 | 0.83 | GRM2 (0.34) | GRM2MAOACALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003515539-A | — | — | 2003-05-07 | — | — | JP | claimed |
| EP-1237895-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | claimed |
| WO-2001040236-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| EP-1286998-B1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-09 | — | — | EP | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| EP-1286998-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1237895-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001040236-A2 | PHOSPHORYLATION OF TERMINAL PRIMARY ALCOHOL GROUPS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | GRM2 3844/4885MAOA 1654/4885CALML3 4622/4885 |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | GRM2 4159/4885MAOA 2239/4885CALML3 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.